Inclusion Criteria:
- - Participants must be ≥18 years of age.
- - Participants must have histologically or cytologically confirmed glioma, with
documented IDH1 and/or IDH2 gene-mutation at time of initial diagnosis.
- - Participants must have radiographic evidence of progression/recurrence per RANO
criteria for low grade gliomas (LGG) on MRI scan.
- - Participants must be willing and able to get serial MRI scans.
- - Participants must have surgically accessible tumors and be surgical candidates.
- - Participants must be ≥12 weeks from completion of radiation to the CNS.
- - Participants must have a baseline brain MRI scan within 21 days prior to Day 1 of
treatment.
- - Participants must be on a stable or decreasing dose of glucocorticoids for 7 days
prior to registration.
- - Patient must have Karnofsky Performance Score (KPS) ≥ 70.
- - Patient must have expected survival of ≥ 6 months.
- - Participant must have adequate organ function, defined as follows:
- Absolute neutrophil count ≥ 1,500/μL.
- - Platelets ≥ 100,000/μL.
- - Calculated creatinine clearance ≥ 30 mL/min/1.73 m2 using the Cockcroft- Gault
equation.
- - Total bilirubin ≤ 1.5 x ULN (≤2.0 in patients with known Gilberts syndrome) OR
direct bilirubin ≤ 1 x ULN.
- - Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x ULN unless liver
metastases are present, in which case they must be ≤ 5 x ULN.
- - Patient must be recovered from any clinically relevant toxic effects of any prior
surgery, radiotherapy, or other therapy intended for the treatment of cancer.
(Patients with residual Grade 1 toxicity due to prior chemotherapy or alopecia of any
grade are allowed).
- - Participant must agree to not donate blood during the study or for 90 days after the
last dose of study treatment.
- - Female participant has a negative urine or serum pregnancy test within 3 days prior to
taking study treatment if of childbearing potential and agrees to abstain from
activities that could result in pregnancy from screening through 180 days after the
last dose of study treatment, or is of non-childbearing potential.
Non-childbearing
potential is defined as follows (by other than medical reasons):
- - ≥45 years of age and has not had menses for >1 year.
- - Patients who have been amenorrhoeic for <2 years without history of a
hysterectomy and oophorectomy must have a follicle stimulating hormone value in
the postmenopausal range upon screening evaluation.
- - Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation.
Documented hysterectomy or oophorectomy must be confirmed with medical records of
the actual procedure or confirmed by an ultrasound. Tubal ligation must be
confirmed with medical records of the actual procedure, otherwise the patient
must be willing to use 2 adequate barrier methods throughout the study, starting
with the screening visit through 180 days after the last dose of study treatment.
Note: Abstinence is acceptable if this is the established and preferred
contraception for the patient.
- - Participant must agree to not breastfeed during the study or for 30 days after
the last dose of study treatment.
- - Male participant agrees to use an adequate method of contraception starting with the
first dose of study treatment through 90 days after the last dose of study treatment.
Note: Abstinence is acceptable if this is the established and preferred contraception
for the patient.
- - Participant must be able to understand the study procedures and agree to participate
in the study by providing written informed consent.
Exclusion Criteria:
- - Participants must have radiographic evidence of primarily disease
progression/recurrence per RANO criteria for low grade gliomas (LGG).
- - Participant must not be simultaneously enrolled in any interventional clinical trial.
- - Participant must not have had major surgery ≤ 4 weeks prior to initiating protocol
therapy and participant must have recovered from any surgical effects.
- - Patients may not have received systemic anticancer therapy <28 days prior to their
first day of study drug administration.
Participants may not have received lomustine <
6 weeks prior to the first day of study drug.
- - Patients who received an investigational agent <28 days prior to their first day of
study drug administration.
- - Participant must not have received a transfusion (platelets or red blood cells) ≤ 4
weeks prior to initiating protocol therapy.
Participant must not have received
colony-stimulating factors (e.g., granulocyte colony-stimulating factor, granulocyte
macrophage colony-stimulating factor, or recombinant erythropoietin) within 4 weeks
prior initiating protocol therapy.
- - Participant has had any known Grade 3 or 4 anemia, neutropenia or thrombocytopenia due
to prior chemotherapy that persisted > 4 weeks and was related to the most recent
treatment.
- - Participant must not have a serious, uncontrolled medical disorder, nonmalignant
systemic disease, or active, uncontrolled infection.
Examples include, but are not
limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial
infarction, uncontrolled major seizure disorder, unstable spinal cord compression,
superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining
informed consent.
- - Participant must not have had diagnosis, detection, or treatment of another type of
cancer ≤ 2 years prior to initiating protocol therapy (except basal or squamous cell
carcinoma of the skin and cervical cancer that has been definitively treated).
- - Participants who are pregnant or breast-feeding.
- - Participants with known hypersensitivity to any of the components of niraparib.
- - Participants with known infection with human immunodeficiency virus (HIV) or active
hepatitis B or C.
- - Participants with any other medical or psychological condition, deemed by the
Investigator to be likely to interfere with a patient's ability to sign informed
consent, cooperate, or participate in the study.
- - Participants with known dysphagia, short-gut syndrome, gastroparesis, or other
conditions that limit the ingestion or gastrointestinal absorption of drugs
administered orally.
- - Participants that have had radiation therapy encompassing >20% of the bone marrow
within 2 weeks; or any radiation therapy within 1 week prior to Day 1 of protocol
therapy.
- - Participant must not have known or symptomatic leptomeningeal metastases.
